Results 301 to 310 of about 808,538 (334)

Preclinical studies of glimepiride

Drugs of Today, 1998
The treatment of NIDDM is advancing on a number of fronts, ranging from the understanding of the mechanisms of action of existing agents to the development of new drugs. Glimepiride, the most recently U.S. approved sulfonylurea, is evaluated for its pancreatic and extrapancreatic activities in addition to safety, when compared with glibenclamide in ...
C, Nguyen, J, Pan, M A, Charles
openaire   +2 more sources

Oncolytic virus preclinical toxicology studies

Journal of Applied Toxicology, 2022
AbstractWith the ever‐emerging concerns of patient safety during medical care, the search for treatments as safe as possible is a priority, especially when focusing on cancer treatment of which therapies often go hand in hand with severe side effects.
Agnija Rasa, Pēteris Alberts
openaire   +2 more sources

Capecitabine: Preclinical Pharmacology Studies

Investigational New Drugs, 2000
Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is a novel fluoropyrimidine carbamate, which was designed to be sequentially converted to 5-fluorouracil (5-FU) by three enzymes located in the liver and in tumors; the final step is the conversion of 5'-deoxy-5-fluorouridine (5'-DFUR) to 5-FU by thymidine phosphorylase (dThdPase) in tumors.
openaire   +2 more sources

Casodex: Preclinical Studies

1996
Antiandrogens are effective drugs in the treatment of advanced prostatic cancer. The main problems associated with their use are their short half-lives, leading to fluctuating serum levels, and their non-selectivity, which leads to increases in serum LH and testosterone through centrally-mediated actions.
openaire   +2 more sources

Preclinical toxicology studies with tobramycin

Toxicology and Applied Pharmacology, 1973
Abstract Tobramycin, an aminoglycoside antibiotic, has been administered to mice, rats, cats and dogs for toxicologic evaluation. The sc LD50 values in mice and rats were 441 and 969 mg/kg, respectively. Deaths were preceded by CNS depression and occurred within 1 hr of treatment.
J S, Welles, J L, Emmerson, W R, Gibson, R, Nickander, N V, Owen, R C, Anderson   +5 more
openaire   +2 more sources

Preclinical studies with Erlotinib (Tarceva)

Seminars in Oncology, 2003
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available, highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase. Inhibition of tyrosine kinase activity prevents HER1/EGFR phosphorylation, the associated downstream signaling events, and may block tumorigenesis mediated by ...
Robert W, Akita, Mark X, Sliwkowski
openaire   +2 more sources

Preclinical safety studies of cefmetazole

Journal of Antimicrobial Chemotherapy, 1989
In order to assess the safety of cefmetazole, preclinical multiple-dose parenteral studies, varying from one to three months in length, were conducted in Sprague-Dawley rats and beagle dogs. Although the largest doses used were in multiples of several times the weight-adjusted doses intended for humans, cefmetazole was generally well tolerated.
J B, Moe, R C, Piper, H, Tanase, K, Sotani, J, Manabe   +4 more
openaire   +2 more sources

Preclinical Studies with Small Animal PET

PET Clinics, 2011
Because no effective cures are available for cutaneous malignant melanoma, early diagnosis and accurate staging are of the utmost importance in increasing patient survival. Fluorodeoxyglucose positron emission tomography (PET)/computed tomography is a functional imaging technique that has contributed to ameliorating surveillance of patients with ...
NANNI, CRISTINA, FANTI, STEFANO
openaire   +3 more sources

Forodesine – Preclinical Studies

Hematology Meeting Reports, 2009
Chemically forodesine is [(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol]. The agent is also known as immucillin hypoxanthine (immucillin H) or BCX-1777. This is a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP).
openaire   +1 more source

Preclinical Study Design for rAAV

2011
The process of moving a novel drug such as an adeno-associated viral vector from the bench top to bedside is an arduous process requiring coordination and skill from multiple laboratories and regulatory agencies. Proceeding to a phase I safety trial in humans after most of the proof-of-concept data have been acquired may take several years. During this
Terence R, Flotte, Thomas J, Conlon, Christian, Mueller   +2 more
openaire   +2 more sources